Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 112


Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.

Nordenskjöld A, Fohlin H, Fornander T, Löfdahl B, Skoog L, Stål O.

Breast Cancer Res Treat. 2016 Nov;160(2):313-322.


Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study.

Colzani E, Clements M, Johansson AL, Liljegren A, He W, Brand J, Adolfsson J, Fornander T, Hall P, Czene K.

Br J Cancer. 2016 Oct 4. doi: 10.1038/bjc.2016.314.


Can breast cancer register data on recommended adjuvant treatment be used as a proxy for actually given treatment?

Wennman-Larsen A, Nilsson MI, Saboonchi F, Olsson M, Alexanderson K, Fornander T, Sandelin K, Petersson LM.

Eur J Oncol Nurs. 2016 Jun;22:1-7. doi: 10.1016/j.ejon.2016.02.010. Epub 2016 Feb 27.


Met and its ligand HGF are associated with clinical outcome in breast cancer.

Veenstra C, Pérez-Tenorio G, Stelling A, Karlsson E, Mirwani SM, Nordensköljd B, Fornander T, Stål O.

Oncotarget. 2016 Jun 14;7(24):37145-37159. doi: 10.18632/oncotarget.9268.


EPH/ephrin profile and EPHB2 expression predicts patient survival in breast cancer.

Husa AM, Magić Ž, Larsson M, Fornander T, Pérez-Tenorio G.

Oncotarget. 2016 Apr 19;7(16):21362-80. doi: 10.18632/oncotarget.7246.


Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer.

Hilborn E, Gacic J, Fornander T, Nordenskjöld B, Stål O, Jansson A.

Br J Cancer. 2016 Feb 2;114(3):248-55. doi: 10.1038/bjc.2015.464. Epub 2016 Jan 7.


ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer.

Manna S, Bostner J, Sun Y, Miller LD, Alayev A, Schwartz NS, Lager E, Fornander T, Nordenskjöld B, Yu JJ, Stål O, Holz MK.

Clin Cancer Res. 2016 Mar 15;22(6):1421-31. doi: 10.1158/1078-0432.CCR-15-0857. Epub 2015 Nov 5.


HER4 tumor expression in breast cancer patients randomized to treatment with or without tamoxifen.

Göthlin Eremo A, Tina E, Wegman P, Stål O, Fransén K, Fornander T, Wingren S.

Int J Oncol. 2015 Oct;47(4):1311-20. doi: 10.3892/ijo.2015.3108. Epub 2015 Jul 28.


Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann B, van de Velde C, Pan H, Peto R, Davies C, Gray R.

Lancet. 2015 Oct 3;386(10001):1341-52. doi: 10.1016/S0140-6736(15)61074-1. Epub 2015 Jul 23.


Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans V, Pan H, Peto R, Bradley R, Gray R.

Lancet. 2015 Oct 3;386(10001):1353-61. doi: 10.1016/S0140-6736(15)60908-4. Epub 2015 Jul 23. Erratum in: Lancet. 2016 Jan 2;387(10013):30.


Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer.

Karlsson E, Veenstra C, Emin S, Dutta C, Pérez-Tenorio G, Nordenskjöld B, Fornander T, Stål O.

Breast Cancer Res Treat. 2015 Aug;153(1):31-40. doi: 10.1007/s10549-015-3516-y. Epub 2015 Jul 25.


Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.

Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF; Austrian Breast and Colorectal Cancer Study Group.

Lancet. 2015 Aug 1;386(9992):433-43. doi: 10.1016/S0140-6736(15)60995-3. Epub 2015 May 31.


S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts.

Bostner J, Karlsson E, Eding CB, Perez-Tenorio G, Franzén H, Konstantinell A, Fornander T, Nordenskjöld B, Stål O.

Endocr Relat Cancer. 2015 Jun;22(3):331-43. doi: 10.1530/ERC-14-0513.


The RAD51 135G>C polymorphism is related to the effect of adjuvant therapy in early breast cancer.

Söderlund Leifler K, Asklid A, Fornander T, Stenmark Askmalm M.

J Cancer Res Clin Oncol. 2015 May;141(5):797-804. doi: 10.1007/s00432-014-1859-0. Epub 2014 Oct 30.


VAV3 mediates resistance to breast cancer endocrine therapy.

Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X, Serra-Musach J, Islam A, Caizzi L, Di Croce L, Nevedomskaya E, Zwart W, Bostner J, Karlsson E, Pérez Tenorio G, Fornander T, Sgroi DC, Garcia-Mata R, Jansen MP, García N, Bonifaci N, Climent F, Soler MT, Rodríguez-Vida A, Gil M, Brunet J, Martrat G, Gómez-Baldó L, Extremera AI, Figueras A, Balart J, Clarke R, Burnstein KL, Carlson KE, Katzenellenbogen JA, Vizoso M, Esteller M, Villanueva A, Rodríguez-Peña AB, Bustelo XR, Nakamura Y, Zembutsu H, Stål O, Beijersbergen RL, Pujana MA.

Breast Cancer Res. 2014 May 28;16(3):R53. doi: 10.1186/bcr3664.


Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.

Sjöström M, Hartman L, Grabau D, Fornander T, Malmström P, Nordenskjöld B, Sgroi DC, Skoog L, Stål O, Leeb-Lundberg LM, Fernö M.

Breast Cancer Res Treat. 2014 May;145(1):61-71. doi: 10.1007/s10549-014-2936-4. Epub 2014 Apr 9.


C-X-C ligand 10 and C-X-C receptor 3 status can predict tamoxifen treatment response in breast cancer patients.

Hilborn E, Sivik T, Fornander T, Stål O, Nordenskjöld B, Jansson A.

Breast Cancer Res Treat. 2014 May;145(1):73-82. doi: 10.1007/s10549-014-2933-7. Epub 2014 Apr 9.


Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.

EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S.

Lancet. 2014 Jun 21;383(9935):2127-35. doi: 10.1016/S0140-6736(14)60488-8. Epub 2014 Mar 19. Erratum in: Lancet. 2014 Nov 22;384(9957):1848.


Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study.

Au HJ, Eiermann W, Robert NJ, Pienkowski T, Crown J, Martin M, Pawlicki M, Chan A, Mackey J, Glaspy J, Pintér T, Liu MC, Fornander T, Sehdev S, Ferrero JM, Bée V, Santana MJ, Miller DP, Lalla D, Slamon DJ; Translational Research in Oncology BCIRG 006 Trial Investigators.

Oncologist. 2013;18(7):812-8. doi: 10.1634/theoncologist.2013-0091. Epub 2013 Jun 28.

Items per page

Supplemental Content

Loading ...
Support Center